US 11,912,727 B2
Arginase inhibitors and methods of use thereof
Scott Nathan Mlynarski, Waltham, MA (US); Tyler Grebe, Waltham, MA (US); Sameer Kawatkar, Waltham, MA (US); Maurice Raymond Verschoyle Finlay, Cambridge (GB); Iain Simpson, Cambridge (GB); Jianyan Wang, Waltham, MA (US); Steve Cook, Waltham, MA (US); and Dedong Wu, Waltham, MA (US)
Assigned to AstraZeneca AB, Sodertalje (SE)
Filed by AstraZeneca AB, Sodertalje (SE)
Filed on Jul. 10, 2023, as Appl. No. 18/349,336.
Application 18/349,336 is a continuation of application No. 17/812,736, filed on Jul. 15, 2022.
Application 17/812,736 is a continuation of application No. 16/969,739, granted, now 11,420,984, issued on Aug. 23, 2022, previously published as PCT/IB2019/051236, filed on Feb. 15, 2019.
Claims priority of provisional application 62/778,002, filed on Dec. 11, 2018.
Claims priority of provisional application 62/671,576, filed on May 15, 2018.
Claims priority of provisional application 62/631,659, filed on Feb. 17, 2018.
Claims priority of provisional application 62/721,113, filed on Aug. 22, 2018.
Prior Publication US 2023/0365599 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 5/00 (2006.01); A61K 31/69 (2006.01); C07F 5/02 (2006.01)
CPC C07F 5/025 (2013.01) 13 Claims
 
1. A compound of formula (II), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein
R2 is —OH or —NHR2a;
R2a is —H or —C(O)CH(R2b)NH2; and
R2b is —CH3 or —CH(CH3)2.